Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
McKesson
Medtronic
Colorcon

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Olmesartan medoxomil - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for olmesartan medoxomil and what is the scope of freedom to operate?

Olmesartan medoxomil is the generic ingredient in two branded drugs marketed by Daiichi Sankyo, Accord Hlthcare, Alembic Pharms Ltd, Alkem Labs Ltd, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, Mylan, Qilu Pharm Co Ltd, Sciegen Pharms Inc, Sunshine Lake, Teva Pharms Usa, Torrent, Umedica Labs Pvt Ltd, and Zydus Pharms, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-six drug master file entries for olmesartan medoxomil. Twenty-five suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for olmesartan medoxomil

See drug prices for olmesartan medoxomil

Recent Clinical Trials for olmesartan medoxomil

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pharmtechnology LLCPhase 1
Altasciences Company Inc.Phase 1
Daiichi Sankyo Co., Ltd.Phase 3

See all olmesartan medoxomil clinical trials

Recent Litigation for olmesartan medoxomil

Identify potential future generic entrants

District Court Litigation
Case NameDate
Apotex Inc. v. Daiichi Sankyo, Inc.2016-05-16
Aurobindo Pharmaceuticals Limited v. Daiici Sankyo, Inc.2016-05-02
Apotex Inc v. Daiichi Sankyo, Inc.2015-04-27

See all olmesartan medoxomil litigation

Generic filers with tentative approvals for OLMESARTAN MEDOXOMIL
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial40MGTABLET; ORAL
  Start Trial  Start Trial20MGTABLET; ORAL
  Start Trial  Start Trial5MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for olmesartan medoxomil
Medical Subject Heading (MeSH) Categories for olmesartan medoxomil
Synonyms for olmesartan medoxomil
(5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-h
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-i midazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-iMidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)-4-biphenylyl]methyl]-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
(5-Methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazol-5-carboxylate;
(5-Methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylate
144689-63-4
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
5-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-3-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-3H-IMIDAZOLE-4-CARBOXYLIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
689O634
6M97XTV3HD
A808260
AB0012006
AB01275443_02
AB01275443_03
AB01275443-01
AB1009487
AC-1601
AC1L2Y71
AKOS015894907
AKOS015914772
AN-1125
AOB3863
BC208264
BC209016
BCP05214
BCP9000555
BDBM50442892
Benevas
Benicar
Benicar (TN)
BR-72894
BRD-K78485176-001-02-9
BRD-K78485176-001-03-7
BSPBio_003491
C29H30N6O6
CAS-144689-63-4
CCG-221184
CCG-39596
CHEBI:31932
CHEMBL1200692
CPD004727564
CS-0577
CS-866
CS-866DM
CS-866RN
CS866
D01204
DSSTox_CID_25924
DSSTox_GSID_45924
DSSTox_RID_81226
DTXSID9045924
EBD35964
FT-0601603
GTPL591
HMS1922L15
HMS2089K18
HMS2093K16
HMS3651E13
HMS3715N09
HY-17005
I06-0025
I14-41691
J-501595
J10058
KBio2_002490
KBio2_005058
KBio2_007626
KBio3_002711
KBioGR_001040
KBioSS_002498
KS-00000IVQ
KS-1182
L001061
LS-181818
MCULE-2480015750
MLS006010109
NCGC00095136-01
NCGC00095136-02
NCGC00095136-03
NSC-758924
NSC758924
O0510
Olmesartan (medoxomil)
Olmesartan medoxomil (Benicar)
Olmesartan medoxomil (JP17/USAN)
Olmesartan medoxomil [USAN:INN:BAN]
Olmesartan medoxomil for system suitability, European Pharmacopoeia (EP) Reference Standard
Olmesartan medoxomil tablets (JP17)
Olmesartan medoxomil, >=98% (HPLC)
Olmesartan medoxomil, European Pharmacopoeia (EP) Reference Standard
Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material
Olmesartan medoxomil, United States Pharmacopeia (USP) Reference Standard
Olmesartan medoxomil|4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-carboxylic acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Olmetec
Olmetec (TN)
Olmetec; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1Htetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
Olsertain
Olvance
Openvas
Pharmakon1600-01505205
RP17784
S-1787
s1604
SAM001246634
SB19327
SBI-0206741.P001
SC-17112
SCHEMBL16403
SMR002203616
SPBio_000431
Spectrum_001944
SPECTRUM1505205
Spectrum2_000506
Spectrum3_001676
Spectrum4_000740
Spectrum5_001556
SR-05000001987
SR-05000001987-1
SR-05000001987-2
ST24031498
STL451024
SW199650-2
Tox21_111445
UNII-6M97XTV3HD
UQGKUQLKSCSZGY-UHFFFAOYSA-N
votume
Z1550675457
ZINC4149248
Paragraph IV (Patent) Challenges for OLMESARTAN MEDOXOMIL
Tradename Dosage Ingredient NDA Submissiondate
BENICAR TABLET;ORAL olmesartan medoxomil 021286 2006-04-25

US Patents and Regulatory Information for olmesartan medoxomil

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jubilant Generics OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 205482-001 Apr 24, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Zydus Pharms OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 205192-002 Apr 24, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sunshine Lake OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 211049-003 Feb 22, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Torrent OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 202375-002 Apr 24, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 091079-003 Apr 24, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for olmesartan medoxomil

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-001 Apr 25, 2002   Start Trial   Start Trial
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-004 Apr 25, 2002   Start Trial   Start Trial
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-003 Apr 25, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Johnson and Johnson
Mallinckrodt
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.